MannKind Corporation
Health Care · Biotechnology
Lately:3 news stories in 90 daysFollow changes →
Facts
as of Nov 22, 2026Drawing on the legacy of innovator and humanitarian Alfred E. Mann, our team of passionate scientists, researchers, and professionals develops cutting-edge therapeutic products and technologies that help people take control of their health and live—fully humann.
- Legal name
- MANNKIND CORP
- Employees
- 501-1000estimated range
- Listing
- NASDAQ: MNKD
- Register numbers
- EIN 133607736
- Official records
- Wikidata Q6750663LEI 213800GFBCNY1ZFST722SEC CIK 899460
- Website
- mannkindcorp.com
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Funding
Full ledger, 2 records →MannKind Corporation has $227.7M paid in by investors, lenders and donors.
$227.7MPaid in
Money innewest first
$138.9MPaid
$88.8MPaid
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Ownership
All holders and entities →MannKind Corporation operates through 1 legal entity in 1 country.
Legal entities1 in 1 country
MANNKIND CORP
operator · US EIN 133607736
US
Holders and shares as each register or filing states them.
Products
Products →MannKind Corporation has 59 clinical trials on record, 2 under way. MannKind Corporation paid US doctors and teaching hospitals $527k in 2025, and $2.3M for research (CMS Open Payments).
Clinical trials
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
phase 2 · under way · 153 participants · Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)
May 2026
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
phase 2 · under way · 100 participants · Type 1 Diabetes Mellitus
Feb 2026
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
phase 1 · completed · 27 participants · Idiopathic Pulmonary Fibrosis (IPF)
Dec 2025
Wikipedia readersen.wikipedia.org
Nov 2024Oct 2026 · 444
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Risk
Full record →MannKind Corporation: 13 research papers in five years, $20k of EU lobbying in 2026.
Legal entity active
MANNKIND CORP
Not checked
No match
None
None
$20k
Patents
37
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Newsroom
NewsMannKind stock adds an inhaled GLP-1 licensing deal
Sep 29
Newskalkinemedia.com
Sep 25
Sources: the outlets named on each headline, each story once
